Levetiracetam Oral Solution of Actavis approved in the US

Distribution of the Levetiracetam Oral Solution has commenced as Actavis received approval from the US Food & Drug Administration (FDA) for US market.

Levetiracetam Oral Solution is the generic equivalent of Keppra® Oral Solution by UCB, Incorporated and it is available in the 100mg/mL strength. Levetiracetam Oral Solution is used in the treatment of partial onset seizures in adults and children with epilepsy. Annual U.S. sales of Keppra® Oral Solution were US$95.9 million for the 12 months ending September 2008 according to IMS Health data.

“The approval of Levetiracetam Oral Solution demonstrates our continuing commitment to introduce new generic products to the marketplace, as well as highlights our expertise in developing and manufacturing a wide range of dosage forms. Actavis’ drive to be a leader in generic pharmaceuticals is supported by one of the largest product development pipelines in the industry, ” commented Doug Boothe, CEO of Actavis in the United States on the new approval.

Contact Information

Hjordis Arnadottir

Director, External Communications

Actavis Group

Contact via E-mail